A subsidiary has been "blacklisted" by Shenzhen for one year. Jointown Pharmaceutical Group claims to be "in the process of defending". The industry believes that the intensity of procurement supervision is continuously increasing.

Recently, Jointown Pharmaceutical Group's subsidiary, Jointown Medical Device, was fined and banned from participating in Shenzhen procurement for one year due to providing false information in a tender at a hospital in Shenzhen. Jointown Pharmaceutical Group responded to a reporter from Caijing.com.cn, stating that this incident is a pending matter, and they have organized appeal materials and are currently undergoing administrative reconsideration. This year, several listed companies have been fined for violations in the bidding and procurement process, leading industry insiders to suggest that companies should pay more attention to compliance with details during the bidding process.

cls.cnSep 6 17:24

Head accounting firms have also been heavily penalized, with penalties directly related to ten violations. Currently, there are 53 IPO projects under review.

luoxin pharmaceuticals group stock's financial report audit has ten major professional issues, Tianjian Accounting Firm has been warned; Tianjian Accounting Firm is currently conducting audits for a total of 86 projects, including 53 IPO projects under review; 34 accounting firms have been fined this year, and the key is to strengthen the responsibility of the 'gatekeepers'.

cls.cnAug 30 20:24

Zhejiang Jolly Pharmaceutical: The regions that won the centralized procurement bids have basically achieved volume-based pricing and will develop 10 varieties of Wuling series.

①The company has seen both gains and losses in centralized procurement, for example, sales in centralized procurement areas have increased significantly compared to non-centralized procurement areas, but the company once lost the bid in the procurement of Bacillus Subtilis; ②Due to the reduction of sales expenses and other reasons, the net income of the company in the areas where it won the bid in centralized procurement has actually increased; ③Currently, the company's production capacity utilization rate of Trametes versicolor powder is relatively high and expansion projects for the second phase are underway, with future considerations for planning new production capacity.

cls.cnAug 27 16:47

Affected by centralized procurement, Yabao Pharmaceutical: The cancellation of product qualification for hanging network by Hebei has a relatively small impact on profits. | Direct entry into the earnings conference.

①The chairman of Yabao Pharmaceutical Group stated that the cancellation of the qualification for many products in Hebei had a relatively small impact on profit. ②The sales of H1 Escitalopram Injection were affected by centralized procurement, leading to a slight decrease in the company's sales revenue. ③Sales of Dinggui's Navel Patch are seasonal, with a slight decrease in revenue in the second quarter.

cls.cnAug 26 13:40

High inventory coupled with industry pressure, Chongqing Taiji Industry's H1 revenue and net profit both declined. | Interpretation of financial statements.

In the first half of this year, chongqing taiji industry's net profit was 0.495 billion yuan, a year-on-year decrease of 12.51%; The company stated that the poor performance in the first half of the year was mainly due to the high base of the same period last year and the high social inventory of some products.

cls.cnAug 22 23:19

COVID-19 drugs are achieving widespread sales, and concept stocks are approaching their limit-up. This week, institutions are conducting research on many related listed companies.

① Huluwa released agency research notes on Wednesday, stating that the COVID-19 drug product pediatric pulmonary fever cough and asthma granules has been widely sold in both the hospital and outside the hospital. The company closed close to rising or stopping on Monday. ② Sort out the industry sectors that organizations are most concerned about this week (attached table), the list of listed companies (attached shares), and the latest research on the COVID-19 drug industry.

cls.cnAug 18 21:52